DACOGEN
About DACOGEN: Treatment for Myelodysplastic Syndromes (MDS)
DACOGEN™ (decitabine) for Injection is a hypomethylating agent indicated to treat patients with myelodysplastic syndromes (MDS), including previously treated and untreated MDS, de novo and secondary MDS of all French-American-British (FAB) subtypes (RA, RARS, RAEB, RAEB-t, CMML*), and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups.
